The abstract is read at the publisher; the summary is JClub's.
Stem cell and hepatocyte transplantation, plus liver organoid and 3D bioprinting approaches, are linked to improved outcomes and new graft sources for end-stage liver disease.
- Why it matters: Donor scarcity means many patients die before liver transplantation, creating a need for alternative therapies that can extend survival and expand transplantable liver tissue.
- What they did: The review synthesizes recent progress across stem cell transplantation, hepatocyte transplantation, in vitro liver tissue generation (including liver organoids and three-dimensional bioprinting), and liver replacement technologies, highlighting clinical studies and tissue-engineering methods.
- The result: Evidence from clinical studies suggests these cell-based approaches can prolong survival and act as a bridge to liver transplantation, while organogenesis-mimicking technologies may provide transplantable hepatic tissues with complex structure and function.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.